Levodopa therapy for Parkinson's disease: challenges and future prospects.
Olanow
C Warren
CW
Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA. warren.olanow@mssm.edu
Lees
Andrew
A
Obeso
Jose
J
D000203:Activities of Daily Living; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007980:Levodopa / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D011788:Quality of Life; D014839:Vomiting / Q000139:chemically induced
D000978:Antiparkinson Agents; D007980:Levodopa